Drug Approvals International – Page 129 – All about Drugs Live by Dr Anthony Melvin Crasto

Linrodostat BMS 986205

cas 2221034-29-1 Linrodostat (2R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide Linrodostat mesylate Linrodostat [USAN] UNII-OS7OBU191R OS7OBU191R Linrodostat mesylate [USAN] BMS-986205-04 2221034-29-1 Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha- methyl-, (alphaR,1alpha,4alpha)-, methanesulfonate (1:1) Linrodostat; (2R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; Linrodostat mesylate; Linrodostat [USAN]; UNII-OS7OBU191R; OS7OBU191R BMS 986205 (2R)-N-(4-Chlorophenyl)-2-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]propanamide Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis- Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis-(αR)- (i?)-N-(4-chlorophenyl)-2- c 5-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide CAS: 1923833-60-6 Phase III Head and neck cancer; Malignant melanoma BMS-986205, ONO-7701, F- 001287 Molecular Formula C24H24ClFN2O Average …

Metopimazine

Metopimazine RP-9965, EXP-999, NG-101 l-(3-[2-(methylsulfonyl)-10H-phenothiazin-10-yl]propyl)-4-piperidinecarboxamide CAS 14008-44-7 MF C22 H27 N3 O3 S2 MW 445.60 4-Piperidinecarboxamide, 1-[3-[2-(methylsulfonyl)-10H-phenothiazin-10-yl]propyl]- Isonipecotamide, 1-[3-[2-(methylsulfonyl)phenothiazin-10-yl]propyl]- (7CI,8CI) 1-[3-[2-(Methylsulfonyl)-10H-phenothiazin-10-yl]propyl]-4-piperidinecarboxamide 1-[3-[2-(Methylsulfonyl)phenothiazin-10-yl]propyl]-4-piperidinecarboxamide 1-[3-[2-(Methylsulfonyl)phenothiazin-10-yl]propyl]isonipecotamide 2-Methylsulfonyl-10-[3-(4-carbamoylpiperidino)propyl]phenothiazine EXP 999 Metopimazine RP 9965 Vogalene metopimazine (gastroparesis), Neurogastrx Sanofi (Originator) Teva Treatment of Nausea and Vomiting, APPROVED Dopamine D3 receptor antagonist; Dopamine D2 receptor antagonist Gastroprokinetic Metopimazine (INN) is a phenothiazine antiemetic. …

2-pyrazolin-5-one

137-45-1 cas 3-Pyrazolin-5-one (8CI) Pyrazol-3(or 5)-ol (6CI,7CI) 1,2-Dihydro-3H-pyrazol-3-one 1,2-Dihydropyrazol-3-one 1H-Pyrazol-3-ol 1H-Pyrazol-5-ol 3-Hydroxypyrazole 3-Pyrazoline-5-one 3-Pyrazolone 4-Pyrazolin-3-one NSC 520837 Pyrazol-3-ol Pyrazol-5-ol Compound 1: Under stirring, to a solution of 5.81 g (50 mmol) of methyl (2E)-3-methoxyacrylate in methanol (5 mL) was hydrazine hydrate (2.75 g, 55 mmol) added and the mixture was refluxed for 1h. Evaporation …

3-(2-(Benzoylamino)ethyl)-1-phenyl-1H-pyrazol-5-yl benzoate

3-(2-(Benzoylamino)ethyl)-1-phenyl-1H-pyrazol-5-yl benzoate (14). Benzoyl chloride (0.230 mL, 2 mmol) was added to a stirred suspension of amine 6c (276 mg, 1 mmol) in a mixture of anhydrous dichloromethane (10 mL) and 4-methylmorpholine (0.66 mL, 6 mmol) and the mixture was stirred at r.t. for 12 h. Volatile component were evaporated in vacuo and the residue …

FDA approves drug to treat ALS, Radicava (Edaravone) , эдаравон, إيدارافون , 依达拉奉 ,ラジカット,

FDA approves drug to treat ALS 05/05/2017 The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. May 5, 2017 Release The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly …

TEV-37440, CEP-37440

TEV-37440, CEP-37440 CAS 1391712-60-9 Benzamide, 2-[[5-chloro-2-[[(6S)-6,7,8,9-tetrahydro-6-[4-(2-hydroxyethyl)-1-piperazinyl]-1-methoxy-5H-benzocyclohepten-2-yl]amino]-4-pyrimidinyl]amino]-N-methyl- MW C30 H38 Cl N7 O3 Molecular Weight, 580.12 2-[(5-Chloropyrimidin-4-yl)amino]-N-methyl-benzamide; 2-[4-[(6S)-1-Methoxy-2-(methylamino)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol 2-[[5-Chloro-2-[[(6S)-6,7,8,9-tetrahydro-6-[4-(2-hydroxyethyl)-1-piperazinyl]-1-methoxy-5H-benzocyclohepten-2-yl]amino]-4-pyrimidinyl]amino]-N-methylbenzamide 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin- 1 -yl]- 1 -methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide, and is also known as CEP-37440. Applicants: CEPHALON, INC. [US/US]; 41 Moores Road P.O. Box 4011 Frazer, Pennsylvania 19355 (US) Inventors: COURVOISIER, Laurent; (US). JACOBS, Martin J.; (US). OTT, Gregory R.; (US). ALLWEIN, Shawn …

NVP-LXS196

NVP-LXS196 CAS 1874276-76-2 3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide 3-Amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide Molecular Formula: C22H23F3N8O Molecular Weight: 472.476 g/mol Inventors Michael Joseph Luzzio, Julien Papillon,Michael Scott Visser Applicant Novartis Ag Michael Joseph Luzzio Julien Papillon, Michael Scott Visser SYNTHESIS Uveal melanoma (UM) is the most common cancer of the eye in adults (Singh AD. et al., Ophthalmology. 201 1 ; 1 …

2-Thiophenecarboxylic acid, 3-amino-, methyl ester

Methyl 3-amino-2-thiophenecarboxylate Molecular Formula C6H7NO2S Average mass 157.190 Da 2-Thiophenecarboxylic acid, 3-amino-, methyl ester Cas 22288-78-4 MW 157.19, MF C6 H7 N O2 S 1H NMR CDCL3 13C NMR CDCL3 IR MASS 1H NMR PREDICT 13C NMR PREDICT SYNTHESIS 1 By Pokhodylo, Nazariy T. et alFrom Synthetic Communications, 44(7), 1002-1006; 2014 2-Propenenitrile, 3-chloro-, CAS : 871-29-4 SYNTHESIS …

Synthesis of ureas in the bio-alternative solvent Cyrene

Synthesis of ureas in the bio-alternative solvent Cyrene Green Chem., 2017, Advance Article DOI: 10.1039/C7GC00908A, Communication Liam Mistry, Kopano Mapesa, Thomas W. Bousfield, Jason E. Camp The bio-alternative solvent Cyrene was shown to be an alternative to toxic oil-derived solvents for the synthesis of ureas. N-Phenylpyrrolidine-1-carboxamide (6a) 1 Method A: To a stirred solution of …

FDA approves new combination treatment for acute myeloid leukemia, Rydapt (midostaurin)

MIDOSTAURIN FDA approves new combination treatment for acute myeloid leukemia 04/28/2017 The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion …